Volume 14, Issue 4 (2-2001)                   Med J Islam Repub Iran 2001 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
MOSALAEI A. CLINICAL FEATURES AND TREATMENT OUTCOME IN 26 CASES WITH Ki-l (CD30) POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA. Med J Islam Repub Iran 2001; 14 (4) :307-309
URL: http://mjiri.iums.ac.ir/article-1-827-en.html
CLINICAL FEATURES AND TREATMENT OUTCOME IN 26 CASES WITH Ki-l (CD30) POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA
AHMAD MOSALAEI
From the Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, l.R. Iran
Abstract:   (4374 Views)
In order to present the clinical features and outcome of patients with Ki-l positive lymphoma and also the role of treatment modalities in this type of malignant disease, twenty-six patients with peripheral lymphadenopathy and a biopsyproven diagnosis ofKi-l positive lymphoma referring to the Radiation Oncology Department during a seven year period were treated with chemotherapy and radiotherapy according to the stage of the disease and after about 3 years of followup the outcome was evaluated. After an initial complete remission for a few months, most patients in advanced stages and a few cases in early stages developed recurrence for whom chemotherapy was started. The majority achieved remission again. After 3 years of follow 'up 18 of 26 patients were alive with no evidence of disease. As the behavior of this lymphoma is related to initial stage of disease rather than to Ki-l expression, radiation therapy may be an acceptable modality adjunctive to chemotherapy in patients with such lymphomas, particularly in those with localized disease for getting better disease control.
Full-Text [PDF 203 kb]   (1357 Downloads)    
Type of Study: Original Research | Subject: Oncology
Add your comments about this article : Your username or Email:
CAPTCHA
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.